Clinical Trial Update: A Study of Sigvotatug Vedotin in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of Sigvotatug Vedotin in advanced solid tumors is currently recruiting. The trial targets multiple indications, including non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Gastroesophageal Junction Adenocarcinoma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Squamous Cell Carcinoma of Head and Neck
• Stomach Cancer

Drugs mentioned

• Sigvotatug Vedotin

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Status: RECRUITING